Skip to main content
SpringerLink
Log in

The sweet and sour RECORD of rosiglitazone for type 2 diabetes

  • News item
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Home PD, Pocock SJ, BECK-NIELSEN H, Gomis R, HANEFELD M, Jones NP, Komajda M, Mcmurray JJV, RECORD Study Group.Rosiglitazone evaluated for cardiovascular outcomes - an interim analysis. New England Journal of Medicine 357: 28-38, No. 1, 5 Jul 2007

  2. NATHAN DM.Rosiglitazone and cardiotoxicity - weighing the evidence. New England Journal of Medicine 357: 64-66, No. 1, 5 Jul 2007

  3. Drazen JM, Morrissey S, Curfman GD.Rosiglitazone - continued uncertainty about safety. New England Journal of Medicine 357: 63-64, No. 1, 5 Jul 2007

  4. Psaty BM, Furberg CD.The record on rosiglitazone and the risk of myocardial infarction. New England Journal of Medicine 357: 67-69, No. 1, 5 Jul 2007

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

The sweet and sour RECORD of rosiglitazone for type 2 diabetes. React. Wkly. 1155, 4 (2007). https://doi.org/10.2165/00128415-200711550-00010

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128415-200711550-00010

Keywords

Search

Navigation